Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous prostate cancer-specific antigens-pulsed dendritic cells Cellgram-DC-PC

A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous PC-specific antigens-pulsed DCs injected subcutaneously near the inguinal lymph nodes, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the PC cells expressing the antigens, resulting in tumor cell lysis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous dendritic cells Cellgram-DC-PC pulsed with prostate cancer-specific antigens
autologous prostate cancer-specific antigens-pulsed DCs Cellgram-DC-PC
Cellgram-DC-PC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search